Xeris Biopharma Holdings (XERS) EBT (2020 - 2025)
Historic EBT for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.
- Xeris Biopharma Holdings' EBT rose 10325.78% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7616.47%. This contributed to the annual value of -$57.1 million for FY2024, which is 1007.81% up from last year.
- According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBT is $621000.0, which was up 10325.78% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBT ranged from a high of $621000.0 in Q3 2025 and a low of -$50.8 million during Q4 2021
- For the 5-year period, Xeris Biopharma Holdings' EBT averaged around -$18.4 million, with its median value being -$18.4 million (2021).
- Per our database at Business Quant, Xeris Biopharma Holdings' EBT tumbled by 13237.41% in 2021 and then skyrocketed by 10325.78% in 2025.
- Over the past 5 years, Xeris Biopharma Holdings' EBT (Quarter) stood at -$50.8 million in 2021, then skyrocketed by 73.88% to -$13.3 million in 2022, then decreased by 2.7% to -$13.6 million in 2023, then soared by 62.48% to -$5.1 million in 2024, then skyrocketed by 112.15% to $621000.0 in 2025.
- Its EBT stands at $621000.0 for Q3 2025, versus -$1.9 million for Q2 2025 and -$9.2 million for Q1 2025.